Literature DB >> 22507596

Radiofrequency ablation: effect of tumor- and organ-specific pharmacologic modulation of arterial and portal venous blood flow on coagulation diameter in an N1-S1 tumor model.

Luke R Wilkins1, Hanping Wu, John R Haaga, Agata Exner.   

Abstract

PURPOSE: To investigate inherent differences in vasculature of tumors versus normal parenchyma and efficacy of radiofrequency (RF) ablation with glucagon, adenosine, and a combination of the two compared with normal saline solution (NS) controls in an N1-S1 tumor model implanted in Sprague-Dawley rat livers.
MATERIALS AND METHODS: A total of 17 tumors were established in the left lobes of rats. Tumor perfusion relative to surrounding liver parenchyma was evaluated with contrast-enhanced ultrasound with intermittent-bolus technique before and after administration of glucagon, adenosine, a combination of the two, or NS. Tumors were ablated with a 22-gauge RF probe with 1 cm of exposed tip at 80 °C for 2 min. Tumor size, zone of necrosis, and viable tumor were measured in tumors after 2,3,5-triphenyltetrazolium chloride staining. Results were compared with degree of tumor perfusion.
RESULTS: The normalized tumor perfusion ratio did not significantly change with administration of NS (1.38% ± 3.93). Vasomodulation resulted in significant decreases in normalized tumor perfusion ratio: 66.22% ± 24.57 (P < .01) with glucagon, 71.45% ± 22.72 (P < .01) with adenosine, and 74.98% ± 16.58 (P < .01) with glucagon plus adenosine. After tumor ablation, there was an increase in size of the ablated area by 100%-165% in the three treatment groups compared with NS controls. Differences among treatment groups were not statistically significant.
CONCLUSIONS: Tumor blood flow may be significantly altered by using systemic injection of appropriate medications. This tumor- and organ-specific approach to tumor vasomodulation may be used to enhance current therapeutic options.
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507596      PMCID: PMC3360825          DOI: 10.1016/j.jvir.2012.02.010

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  23 in total

1.  Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.

Authors:  Andrew Hines-Peralta; Vikas Sukhatme; Meredith Regan; Sabina Signoretti; Zheng-jun Liu; S Nahum Goldberg
Journal:  Radiology       Date:  2006-05-23       Impact factor: 11.105

2.  Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.

Authors:  Bertrand Janne d'Othée; Constantinos T Sofocleous; Nader Hanna; Robert J Lewandowski; Michael C Soulen; Jean-Nicolas Vauthey; Steven J Cohen; Alan P Venook; Matthew S Johnson; Andrew S Kennedy; Ravi Murthy; Jean-Francois Geschwind; Stephen T Kee
Journal:  J Vasc Interv Radiol       Date:  2012-02       Impact factor: 3.464

3.  Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium.

Authors:  M Hayashi; O Matsui; K Ueda; Y Kawamori; M Kadoya; J Yoshikawa; T Gabata; T Takashima; A Nonomura; Y Nakanuma
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

Review 4.  Percutaneous ablation of hepatocellular carcinoma: current status.

Authors:  Justin P McWilliams; Shota Yamamoto; Steven S Raman; Christopher T Loh; Edward W Lee; David M Liu; Stephen T Kee
Journal:  J Vasc Interv Radiol       Date:  2010-08       Impact factor: 3.464

5.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.

Authors:  Shunichi Morikawa; Peter Baluk; Toshiyuki Kaidoh; Amy Haskell; Rakesh K Jain; Donald M McDonald
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

6.  Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals.

Authors:  Martin Krix; Fabian Kiessling; Silvia Vosseler; Isabel Kiessling; Martin Le-Huu; Norbert E Fusenig; Stefan Delorme
Journal:  Ultrasound Med Biol       Date:  2003-08       Impact factor: 2.998

7.  Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.

Authors:  Antoine Hakimé; Andrew Hines-Peralta; Himaja Peddi; Michael B Atkins; Vikas P Sukhatme; Sabina Signoretti; Meredith Regan; S Nahum Goldberg
Journal:  Radiology       Date:  2007-08       Impact factor: 11.105

8.  Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model.

Authors:  Clare Horkan; Muneeb Ahmed; Zhengjun Liu; G Scott Gazelle; Stephanie A Solazzo; Jonathan B Kruskal; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2004-03       Impact factor: 3.464

9.  Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation.

Authors:  Takeshi Hori; Kenji Nagata; Satoru Hasuike; Masaaki Onaga; Mizue Motoda; Akihiro Moriuchi; Hisayoshi Iwakiri; Hirofumi Uto; Jyunya Kato; Akio Ido; Katsuhiro Hayashi; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

10.  Technical aspects of imaging and transfemoral arterial treatment of N1-S1 tumors in rats: an appropriate model to test the biology and therapeutic response to transarterial treatments of liver cancers.

Authors:  Shenghong Ju; Gordon McLennan; Stacy L Bennett; Yun Liang; Laurent Bonnac; Krzysztof W Pankiewicz; Hiremagalur N Jayaram
Journal:  J Vasc Interv Radiol       Date:  2009-01-23       Impact factor: 3.464

View more
  1 in total

1.  Localized hyperthermia with iron oxide-doped yttrium microparticles: steps toward image-guided thermoradiotherapy in liver cancer.

Authors:  Andrew C Gordon; Robert J Lewandowski; Riad Salem; Delbert E Day; Reed A Omary; Andrew C Larson
Journal:  J Vasc Interv Radiol       Date:  2013-12-06       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.